2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term

Vertex Pharmaceuticals (NASDAQ: VRTX) and Mirum Pharmaceuticals (NASDAQ: MIRM) are two biotech stocks that share the same ...

Vertex Pharmaceuticals (VRTX) Valuation Check After FDA Expands ALYFTREK And TRIKAFTA Use

Vertex Pharmaceuticals (VRTX) is back in focus after the U.S. Food and Drug Administration expanded use of its cystic ...

How an unsolved medical mystery became a life-saving breakthrough

Inside the deadly disease confounding medicine, researchers piecing together clues and the breakthrough that meant survival ...
Monthly Prescribing Reference

Alyftrek and Trikafta Now Approved for Broader Cystic Fibrosis Use

The expanded approval was based on clinical and/or in vitro data demonstrating responsiveness across 564 variants for Alyftrek and 521 variants for Trikafta. The label expansions were granted based on ...
Morningstar

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States -With this expansion, any ...
Seeking Alpha

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the ...
Times Argus

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK ® (vanzacaftor ...

What to Expect From Vertex Pharmaceuticals’ Q1 2026 Earnings Report

Vertex Pharmaceuticals is set to report its first-quarter results next month, and analysts are expecting high single-digit ...

Royalty Pharma Declares Second Quarter 2026 Dividend

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ...